Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC